Zufar Mulyukov

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD.

Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD.

Journal: BMJ open ophthalmology

Published: November 25, 2025

Estimation of Maximum Cumulative Administered Activity for Radiopharmaceuticals in Early Clinical Trials: Assessing Long-Term Toxicity Risks of 177Lu-DOTATATE.

Estimation of Maximum Cumulative Administered Activity for Radiopharmaceuticals in Early Clinical Trials: Assessing Long-Term Toxicity Risks of 177Lu-DOTATATE.

Journal: International journal of radiation oncology, biology, physics

Published: September 23, 2025

Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study.

Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study.

Journal: Ophthalmology science

Published: October 20, 2023

Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.

Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.

Journal: Eye (London, England)

Published: January 26, 2022

EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.

EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.

Journal: Retina (Philadelphia, Pa.)

Published: December 19, 2021

Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.

Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.

Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde

Published: December 13, 2021

Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data.

Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data.

Journal: Current eye research

Published: February 18, 2020

Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Journal: JAMA ophthalmology

Published: May 24, 2019

Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach.

Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach.

Journal: Contemporary clinical trials

Published: October 15, 2018

Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.

Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 30, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026